Use of corticosteroid hormones in patients with moderate COVID-19: what goals can be achieved

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: There is strong evidence of the effectiveness of glucocorticoids (dexamethasone) in the treatment of critically ill patients with COVID-19. However, the condition of most of them, at the time of hospitalization, is not assessed as severe or critical, but at the same time, with dynamic observation, it may worsen. It is in this group of patients that data on the effectiveness of glucocorticoids use remain few and contradictory.

AIMS: to study the relationship between the use of a short course of corticosteroid hormones (CSH) in recommended doses and clinical and laboratory parameters of generalized inflammation in patients with a moderate course of new coronavirus infection (COVID-19) in a hospital setting.

MATERIALS AND METHODS: The study included 121 patients with probable (clinically confirmed) and confirmed (laboratory) cases of COVID-19. A retrospective analysis of the data of electronic medical records of all patients admitted sequentially from October 1, 2020 to January 31, 2021 was carried out. The demographic indicators, comorbidities, symptoms, clinical indicators, results of laboratory tests and computed tomography were studied. Statistical analysis was performed using the standard Statistica 10 software for Windows.

RESULTS: The data of electronic medical records of 121 patients were studied. Glucocorticoids were prescribed to 71 patients (58.7%), most often dexamethasone was used 70 out of 71 (98.5%). 73 (60.3%) patients had concomitant chronic diseases. 114 (94.2%) were discharged with recovery. patients, died ― 5 (4.1%), the cause of deaths was multiple organ failure. When evaluating groups of patients, in the period before the appointment of glucocorticoids and a similar period of illness in those who did not receive glucocorticoids significant differences were found in the groups in terms of generalized inflammation (body temperature, C-reactive protein concentration), indicators of respiratory disorders (respiration rate, oxygen saturation), according to indicators of the cellular composition of blood (lymphopenia and thrombocytopenia) in patients treated with glucocorticoids. After completing the course of glucocorticoids, patients showed a statistically significant increase in lymphocytes ― by 76.9%, platelets ― by 67.4%. The level of C-reactive protein significantly decreased by more than 4 times. The obtained data show a decrease in the severity of generalized inflammation, correction of the activation syndrome. acrophages, activation of bone marrow germs and positive clinical and laboratory dynamics of COVID-19.

CONCLUSION: The study demonstrated reliable data on a decrease in the activity of generalized inflammation after the use of a short course of corticosteroid hormones in recommended doses. This led to the stabilization of the state in 53 of 71 (73%) patients and the termination of the escalation of further treatment.

About the authors

Dmitry O. Efremov

3 Central Military Clinical Hospital of a Name of A.A. Vishnevsky

Email: Efremov-d24@mail.ru
ORCID iD: 0000-0001-7889-6052
SPIN-code: 7115-2713
Russian Federation, Krasnogorsk

Vladimir B. Beloborodov

Russian Medical Academy of Continuous Professional Education

Email: belvb@mail.ru
ORCID iD: 0000-0002-0544-4167
SPIN-code: 4233-2046

MD, Dr. Sci. (Med), Professor

Russian Federation, Moscow

Andrey V. Meshkov

3 Central Military Clinical Hospital of a Name of A.A. Vishnevsky

Author for correspondence.
Email: 3hospital_f1@mil.ru
ORCID iD: 0000-0003-3961-6534

MD, Cand. Sci. (Med.)

Russian Federation, Krasnogorsk

References

  1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3
  2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7
  3. Cao J, Tu WJ, Cheng W, et al. Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):748–755. doi: 10.1093/cid/ciaa243
  4. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848. doi: 10.1007/s00134-020-05991-x
  5. Qi J, Zhou Y, Hua J, et al. The scRNA-seq Expression Profiling of the Receptor ACE2 and the Cellular Protease TMPRSS2 Reveals Human Organs Susceptible to SARS-CoV-2 Infection. Int J Environ Res. 2021;18(1):284. doi: 10.3390/ijerph18010284
  6. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(10): 1135–1140. doi: 10.1016/S1473-3099(20)30434-5
  7. De Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203–1207. doi: 10.1038/nm1477
  8. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103. doi: 10.1111/j.1365-2249.2004.02415.x
  9. Cano EJ, Fuentes XF, Campioli CC, et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest. 2021;159(3):1019–1040. doi: 10.1016/j.chest.2020.10.054
  10. Baillie JK, Digard P. Influenza — time to target the host? N Engl J Med. 2013;369(2):191–193. doi: 10.1056/NEJMcibr1304414
  11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5
  12. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474. doi: 10.1126/science.abb8925
  13. Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683–684. doi: 10.1016/S0140-6736(20)30361-5
  14. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475. doi: 10.1016/S0140-6736(20)30317-2
  15. Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the COVID-19 pandemic: rapid review. BMJ. 2020;369:m1936. doi: 10.1136/bmj.m1936
  16. Zhao JP, Hu Y, Du RH, et al. [Expert consensus on the use of corticosteroid in patients with 2019- nCoV pneumonia. (In Chinese)]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):183–184. doi: 10.1016/S0140-6736(20)30361-5
  17. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8): 693–704. doi: 10.1056/NEJMoa2021436
  18. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JA, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341. doi: 10.1001/jama.2020.17023
  19. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585
  20. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi: 10.1136/bmj.m606
  21. Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 8 (03.09.2020)” (approved by the Ministry of Health of Russia). (In Russ). Available from: https://bazanpa.ru/minzdrav-rossii-vremennye-metodicheskie-rekomendatsii-ot03092020-h4869358/. Accessed: 15.10.2020.
  22. Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 9 (26.10.2020)” (approved by the Ministry of Health of Russia). (In Russ). Available from: http://disuria.ru/_ld/8/846_mrC19pdl261020.pdf. Accessed: 15.10.2020.
  23. Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016;42(1):15–31. doi: 10.1016/j.rdc.2015.08.002
  24. Timmermans S, Souffriau J, Libert C. A general introduction to glucocorticoid biology. Front Immunol. 2019;10:1545. doi: 10.3389/fimmu.2019.01545
  25. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233–247. doi: 10.1038/nri.2017.1
  26. Lansbury LE, Rodrigo C, LeonardiBee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated cochrane systematic review and meta-analysis. Crit Care Med. 2020;48(2): e98–e106. doi: 10.1002/14651858.CD010406.pub3
  27. Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opinion on Drug Safety. 2016;15(4):457–465. doi: 10.1517/14740338.2016.1140743
  28. Heming N, Sivanandamoorthy S, Meng P, et al. Immune effects of corticosteroids in sepsis. Front Immunol. 2018;9:1736. doi: 10.3389/fimmu.2018.01736
  29. WHO. World Health Organization; Geneva: Jan 28, 2020. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Available from: https://www.who.int/publications/i/item/10665-332299. Accessed: 15.10.2020.
  30. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with Coronavirus Disease 2019 (COVID19). Med J Aust. 2020;212(9): 416–420. doi: 10.5694/mja2.50577
  31. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8): 693–704. doi: 10.1056/NEJMoa2021436
  32. World Health Organization. Corticosteroids for COVID-19: living guidance, 2 September 2020. Available from: https://apps.who.int/iris/handle/10665/334125. Accessed: 15.10.2020.
  33. Dequin PF, Heming N, Meziani F. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13): 1298–1306. doi: 10.1001/jama.2020.16761
  34. Tomazini BM, Maia IS, Cavalcanti AB. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–1316. doi: 10.1001/jama.2020.17021
  35. Angus DC, Derde L, Al-Beidh F. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–1329. doi: 10.1001/jama.2020.17022
  36. Selvaraj J, Sardar H, Vishnupriya V, et al. Molecular docking analysis of amyloid precursor protein with compounds from the Australian cowplant. Bioinformation. 2020;16(7):561–566. doi: 10.6026/97320630016561
  37. Li Y, Zhou X, Li T, et al. Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study. Emerging Microbes Infect. 2020;9(1):1869–1877. doi: 10.1080/22221751.2020.1807885
  38. Lu X, Chen T, Wang Y, et al. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. Crit Care. 2020;24(1):241. doi: 10.1186/s13054-020-02964-w
  39. Crus F, Ruiz-Antorán B, Muñoz-Gómez A, et al. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother. 2020;64(9):e01168-20. doi: 10.1128/AAC.01168-20
  40. Manjili RH, Zarei M, Habibi M, et al. COVID19 as an acute inflammatory disease. J Immunol. 2020;205(1):12–19. doi: 10.4049/jimmunol2000413
  41. Vassiliou AG, Floros G, Jahaj E, et al. Decreased glucocorticoid receptor expression during critical illness. Eur J Clin Invest. 2019; 49(4):e13073. doi: 10.1111/eci.13073
  42. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi: 10.1093/cid/ciaa248
  43. Cui W, Fan Y, Wu W, et al. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis. 2003;37(6):857–859. doi: 10.1086/378587
  44. Chen Y, Feng Z, Diao B, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) directly decimates human spleens and lymph nodes. medRxiv. 2020. doi: 10.1101/2020.03.27.20045427

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Eco-vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies